Thus, while the serum cytokine signature of increased TNF-α and TRAIL expression observed are indicative of effector cell indirect anti-tumor responses following rLAS-uPA treatment, increased systemic circulating concentrations of these cytokines may also be causes of or contributors to the AE that were observed in the trial. Here, TNF is linked to neoplasm.